<DOC>
	<DOCNO>NCT02316613</DOCNO>
	<brief_summary>This French national , multicenter , prospective , longitudinal , observational study describe treatment modality cohort patient relapse refractory follicular non-Hodgkin 's lymphoma , evaluation cohort overall accord presence MabTheraÂ® ( rituximab ) maintenance therapy . Actively participate physician enroll patient collect therapeutic management data real-life set 5 year .</brief_summary>
	<brief_title>Prospective Observational Study Management Patients With Relapsed Refractory Follicular Lymphoma ( OLYMPE )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient ( age &gt; /= 18 year ) Presenting WHO grade 13 , CD20positive follicular nonHodgkin 's lymphoma , histologically confirm initial diagnosis In relapse ( refractory ) least one line treatment , regardless nature previous treatment ( chemotherapy and/or immunotherapy and/or radioimmunoconjugate therapy and/or radiation+chemotherapy ) decision make give salvage therapy Having receive oral write information study raise objection electronic capture processing his/her personal data Patient participate clinical trial evaluate new , noncommercialized cancer treatment time inclusion Follicular lymphoma present transformation diffuse large cell nonHodgkin 's lymphoma First line treatment radiotherapy alone Initial abstention treatment ( decision treat progression time inclusion OLYMPE study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>